You are here

FDA Approves Tolsura for Systemic Fungal Infections

New Antifungal Has Increased Bioavailability and Reduced Variability

The FDA has approved the new drug application for Tolsura (SUBA-itraconazole, Mayne Pharma). SUBA-itraconazole is indicated for the treatment of certain systemic fungal infections in adult patients.

The new formulation of traconazole is indicated for the treatment of blastomycosis, pulmonary and extrapulmonary; histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis; and aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or refractory to amphotericin B therapy.

These serious infections most commonly occur in vulnerable or immunocompromised patients, for example, those with a history of cancer, transplants, HIV/AIDS, or chronic rheumatic disorders.

Among the most common adverse reactions are nausea, rash, vomiting, edema, headache, diarrhea, fatigue, fever, pruritus, and hypertension.

SUBA-itraconazole 65-mg tablets are expected to be available in January 2019.

Sources: Specialty Pharmacy Times, December 13, 2018; Drugs.com, December 11, 2018

More Headlines

iPSC Therapy Designed to Salvage Eye, Prevent Vision Loss
Health Outcomes Have No Improvement
Adjunctive Therapy is First Generic Version of Sabril for Focal Seizures
Targeted Antibody for FGR3-Positive Mutation
Method Could Lead to Manufacturing Corneas for Transplants
First and Only Second-Generation TKI for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Potential Life-Saving Device Can be Implanted in 2-LB Babies
New Therapy for Patients With HCC Who Previously Received Nexavar
Aggressive Disease Represents Around 6% of All New Cases of NHL